Orifarm
Orifarm, officially known as Orifarm Group, is a prominent player in the pharmaceutical industry, headquartered in Denmark (DK). Founded in 1994, the company has established itself as a leader in the development, production, and distribution of generic medicines and parallel imports, primarily serving the European market. With a strong focus on quality and accessibility, Orifarm offers a diverse portfolio of products, including prescription medications and over-the-counter solutions. Their commitment to innovation and sustainability sets them apart in a competitive landscape. Over the years, Orifarm has achieved significant milestones, including expanding its operational reach across multiple European countries. The company is recognised for its dedication to improving patient access to essential medicines, solidifying its position as a trusted partner in the healthcare sector.
DitchCarbon Score
How does Orifarm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Orifarm's score of 13 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Orifarm's reported carbon emissions
In 2023, Orifarm reported significant carbon emissions, with Scope 1 emissions at approximately 4,420,000 kg CO2e and Scope 2 emissions at about 11,270,000 kg CO2e. This marked a notable increase in emissions compared to previous years, particularly from 2022, where total emissions were around 7,206,000 kg CO2e, with Scope 1 at 4,315,000 kg CO2e and Scope 2 at 7,206,000 kg CO2e. Over the years, Orifarm has demonstrated a commitment to reducing its carbon footprint. The company has set long-term net-zero targets, aiming for a comprehensive reduction across all scopes by 2050. This commitment was formalised in 2023, aligning with the Science Based Targets initiative (SBTi), which underscores their dedication to climate action within the pharmaceuticals, biotechnology, and life sciences sector. Despite the recent rise in emissions, Orifarm's proactive stance on sustainability and climate commitments positions them as a responsible player in the industry, striving to mitigate their environmental impact while working towards ambitious reduction goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 732,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 575,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orifarm is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
